• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy
  • Reports
    • Diabetes Technology Innovations Special Report
    • Continuous Glucose Monitoring (CGM) Market Report

AstraZeneca’s once-weekly diabetes drug wins expanded FDA approval

April 3, 2018 By Sarah Faulkner

AstraZenecaAstraZeneca (NYSE:AZN) said today that the FDA approved its extended-release formulation of exenatide, Bydureon, for use as an add-on therapy to basal insulin in adults with Type II diabetes.

The company’s once-weekly GLP-1 injectable was first approved in the U.S. in 2012.

Bydureon’s expanded use is based on data from AstraZeneca’s 28-week Duration-7 trial, the company explained. Participants treated with Bydureon experienced a mean HbA1c reduction of 0.9% compared to just 0.2% in the placebo group.

The pharmaceutical company also reported that 32.5% of patients in the Bydureon group reached an HbA1c of less than 7% compared to 7% of patients in the placebo group.

The Duration-7 trial did not reveal any new safety findings, AstraZeneca added – the overall rate of hypoglycemia was comparable between both groups.

“Type II diabetes is a complex disease for patients and healthcare providers to manage, which is why we continue to invest in the advancement of science supporting the safety and efficacy of exenatide, even 13 years after the first exenatide formulation was introduced to the market,” Jim McDermott, VP of U.S. medical affairs for AstraZeneca’s diabetes business, said in prepared remarks.

“The Bydureon clinical program is one of the most extensive clinical trial programs of a GLP-1RA to date, having been studied in more than 19,000 patients. With this approval, we are providing another important treatment option for health care providers to consider for patients with type 2 diabetes on basal insulin with inadequate glycemic control,” he added.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: AstraZeneca plc

IN CASE YOU MISSED IT

  • MiniMed claims quick FDA clearance for Fit patch pump
  • Tandem’s Mobi pump wins FDA clearance for 7-day tubeless wearable set
  • Senseonics delivers ‘breakout quarter’ more than doubling Eversense 365 revenue
  • Tandem Diabetes Care names successor as CEO Sheridan retires
  • MiniMed names new CMO ahead of planned retirement

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.
MDO

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
About
Contact us
Listen to our Weekly Podcasts
Advertise

Copyright © 2026 · Arrowfly LLC. All Rights Reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy | Terms & Conditions | RSS